期刊文献+

三阴型乳腺癌改良根治术后T_1~T_2N1M0行辅助性放疗的疗效分析 被引量:1

下载PDF
导出
摘要 目的:分析三阴型乳腺癌改良根治术后T_1~T_2N1M0行辅助性放疗的疗效。方法:随机选取进行乳腺癌治疗的三阴型乳腺癌患者98例为研究对象。根据是否行术后放疗分为观察组61例,对照组37例,所有患者均行改良根治术,观察组同时给予同步放疗,观察两组疗效。结果:观察组患者转移率明显低于对照组,差异有统计学意义(P<0.05);5年生存率和复发率与对照组比较,差异无统计学意义(P>0.05);观察组患者DFS显著高于对照组,差异有统计学意义(P<0.05)。两组患者OS差异无统计学意义(P>0.05)。结论:三阴型乳腺癌改良根治术后T_1~T_2N1M0行辅助性放疗能够明显降低转移率,延长DFS时间。
出处 《吉林医学》 CAS 2019年第5期1010-1011,共2页 Jilin Medical Journal
  • 相关文献

参考文献2

二级参考文献28

  • 1Henderson, I. C., Canellos, G. P. Cancer of the breast: the past decade (second of two parts) [ J ]. The New England journal ofmedicine, 1980,302 ( 2 ) : 78-90.
  • 2Huggins, C., Bergenstal, D. M. Inhibition of human mammary and prostatic cancers by adrenalectomy[ J]. Cancer research,1952, 12(2) :134-141.
  • 3Luft, R. , Olivecrona, H+ Hypophysectomy in man; experiences in metastatic cancer of the breast [ J ]. Cancer, 1955,8 (2) :261-270.
  • 4Prowell, T. M. , Davidson, N. E. What is the role of ovarian abla- tion in the management of primary and metastatic breast cancer to- day? [J:. The oncologist,2004,9(5)507-517.
  • 5Controlled trial of tamoxifen as adjuvant agent in management of ear- ly breast cancer. Interim analysis at four years by Nolvadex Adju- vant Trial Organisation[ Jl. Lancet,1983,1 (8319)257-261.
  • 6Fisher, B. et al. Adjuvant chemotherapy with and without tarnox- ifen in the treatment of primary breast caneer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial[ J]. J Clin Oncol, 1986,4 ( 4 ) :459-471.
  • 7Effects of adjuvant tamoxifen and of eytotoxie therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28, 896 women. Early Breast Cancer Trialists' Collaborative Group [J]. The New England journal of medicine,1988,319(26):1681- 1692.
  • 8Albain, K. S. et al. Adjuvant chemotherapy and timing of tamox- ifen in postmenopausal patients with endoerine-responsive, node- positive breast cancer: a phase 3, open-label, randomised con- trolled trialiJl. Lancet,2009,374(9707) :2055-2063.
  • 9Tamoxilen fur early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group[ J ]. Lan- cet, 1998, 351 (9114) : 1451-1467.
  • 10Fisher, B. , Dignam, J. , Bryant, J. & Wolmark, N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer : updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[ J:. Journal of the Nation- al Cancer Institute,2001,93 (9) : 684-690.

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部